Status:
COMPLETED
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
Lead Sponsor:
Novartis
Conditions:
Schizophrenia
Eligibility:
All Genders
18-64 years
Phase:
PHASE4
Brief Summary
Evaluate the clinical outcome of two switching strategies to iloperidone treatment in adult subjects with schizophrenia who require a change in their current antipsychotic treatment of risperidone, ol...
Eligibility Criteria
Inclusion
- Males or females, 18 to 64 years of age, inclusive
- DSM-IV diagnosis of schizophrenia
- Patients currently on an optimal in-label dose of one of the following permitted antipsychotic treatments for at least 30 days: risperidone, olanzapine, or aripiprazole
- Efficacy Clinical Global Impression of Severity (E-CGI-S) of 4 or 5 or
- Not tolerating one of the permitted treatments and exhibits one of the allowable side-effects
Exclusion
- Any other current Axis I disorder other than schizophrenia which is the focus of treatment;
- Acutely psychotic or patient's symptom severity requires hospitalization
- Patient with significant cardiovascular illness (myocardial infarction, cardiac arrhythmia)
- Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
August 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
501 Patients enrolled
Trial Details
Trial ID
NCT01207414
Start Date
August 1 2010
End Date
January 1 2012
Last Update
March 15 2013
Active Locations (59)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham Psychiatry Pharmaceutical Studies, Inc.
Birmingham, Alabama, United States, 35226
2
Comprehensive Neuroscience
Cerritos, California, United States, 90703
3
ATP Clinical Research Center, Inc.
Costa Mesa, California, United States, 92626
4
Collaborative Neuroscience Network
Garden Grove, California, United States, 92845